Evercore ISI Lifts PT on BioMarin Pharmaceutical: What Investors Should Know Evercore ISI has increased its price target (PT) on BioMarin Pharmaceutical, citing optimistic views on the company's future prospects.
At first glance, this move may seem like a straightforward endorsement of BioMarin's growth potential.
However, upon closer inspection, it becomes clear that Evercore ISI's analysis is based on a nuanced understanding of the biotech industry and its specific position within it.